Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.
The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment
Breast Cancer
DRUG: Vinorelbine|DRUG: Letrozole|DRUG: Anastrozole
Progression free survival (PFS), Proportion of progression or death, up to 6 months
Evaluation of partial and complete response rate by RECIST 1.1, partial and complete response rate by RECIST 1.1 in each arm, up to 6 months|duration of response, duration of response is defined as the time from randomization and the disease progression, up to 6 months|clinical benefit after 24 weeks of treatment, the clinical benefit is defined by the rate of complete response, by the rate of partial response and by the stability of lesions at 24 weeks according to criteria RECIST 1.1, up to 24 weeks|overall survival, the overall survival of patients randomized is defined as the time from randomization and the date of death, up to 2 years|Toxicity according to criteria NCI CTAEv4.03, tolerance of the treatment based on AE occurrence according to criteria NCI CTAEv4.03, up to 2 years|health-related quality of life, health-related quality of life and symptomatic state will be evaluated by filling a questionnaire by patients, up to 2 years
The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment that would have the theoretical advantage of being well tolerated and more effective than chemotherapy alone even after an anti-aromatase therapy.